1. Home
  2. INSM vs BAP Comparison

INSM vs BAP Comparison

Compare INSM & BAP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • BAP
  • Stock Information
  • Founded
  • INSM 1988
  • BAP 1889
  • Country
  • INSM United States
  • BAP Peru
  • Employees
  • INSM N/A
  • BAP N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • BAP Major Banks
  • Sector
  • INSM Health Care
  • BAP Finance
  • Exchange
  • INSM Nasdaq
  • BAP Nasdaq
  • Market Cap
  • INSM 26.0B
  • BAP 21.1B
  • IPO Year
  • INSM 2000
  • BAP 1995
  • Fundamental
  • Price
  • INSM $145.86
  • BAP $261.79
  • Analyst Decision
  • INSM Strong Buy
  • BAP Buy
  • Analyst Count
  • INSM 18
  • BAP 6
  • Target Price
  • INSM $146.81
  • BAP $245.00
  • AVG Volume (30 Days)
  • INSM 2.0M
  • BAP 354.5K
  • Earning Date
  • INSM 10-30-2025
  • BAP 11-06-2025
  • Dividend Yield
  • INSM N/A
  • BAP 4.20%
  • EPS Growth
  • INSM N/A
  • BAP 26.90
  • EPS
  • INSM N/A
  • BAP 22.19
  • Revenue
  • INSM $398,105,000.00
  • BAP $5,576,317,301.00
  • Revenue This Year
  • INSM $31.95
  • BAP $24.04
  • Revenue Next Year
  • INSM $125.46
  • BAP $6.23
  • P/E Ratio
  • INSM N/A
  • BAP $12.54
  • Revenue Growth
  • INSM 21.15
  • BAP 20.05
  • 52 Week Low
  • INSM $60.40
  • BAP $165.51
  • 52 Week High
  • INSM $149.08
  • BAP $280.88
  • Technical
  • Relative Strength Index (RSI)
  • INSM 72.40
  • BAP 53.95
  • Support Level
  • INSM $138.73
  • BAP $264.25
  • Resistance Level
  • INSM $148.22
  • BAP $280.88
  • Average True Range (ATR)
  • INSM 3.85
  • BAP 6.12
  • MACD
  • INSM -0.97
  • BAP -0.08
  • Stochastic Oscillator
  • INSM 78.08
  • BAP 33.97

About INSM Insmed Incorporated

Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.

About BAP Credicorp Ltd.

Credicorp Ltd is a Peruvian financial services company. It operates in four business lines, including Universal Banking, Insurance and Pensions, Microfinance, and Investment Management & Advisory. Its subsidiaries include Banco de Credito del Peru, Prima AFP, and Credicorp Capital. Geographically, the company operates in Peru, Colombia, Bolivia, Chile, Panama, the USA, and Mexico; the majority of its revenue is generated from Peru.

Share on Social Networks: